// App-Quantinova.ai

e14032 : Circulating tumor cell (CTC) PD-L1 and interferon regulatory factor-1 (IRF-1) expression as biomarkers of anti-PD-(L)1 response.

Researchers

Presenter

  • Laura Kennedy

Principal Investigators

  • Arturo B. Ramirez

  • Lance U'Ren

  • Yao Sun

  • Grace Durenberger

  • Laura Quan Man Chow

  • Petros Grivas

  • Vijayakrishna K. Gadi

Medical Centers

  • University of Washington, Seattle, WA

  • RareCyte Inc., Seattle, WA

  • RareCyte Inc., Seattle, WA

  • Fred Hutchinson Cancer Resaerch Center, Seattle, WA

  • Division of Medical Oncology, University of Washington, Seattle, WA

  • University of Washington School of Medicine, Seattle, WA

Locations

  • United States

Companies

  • RareCyte, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Programmed death-ligand 1

  • Epithelial Cell Adhesion Molecule

  • Interferon Regulatory Factor 1

Drug/Treatment

  • Interferon

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved